Bradykinin (BK) is a vasoactive nonapeptide cleaved from circulating kininogens and that is degraded by angiotensin converting enzyme (ACE). It has been reported that the PR3 protease from human neutrophil releases an alternate peptide of 13 amino acids, Met-Lys-BK-Ser-Ser, from high molecular weight kininogen. We have studied vascular actions of this kinin. Its affinity for recombinant B 1 and B 2 receptors is very low, as assessed by the binding competition of 
Introduction
Bradykinin (BK)-related peptides (the kinins) stimulate 2 types of G protein coupled receptors, the B 1 and B 2 receptors after being generated by kallikreins from kininogens [1] . The nonapeptide BK itself, generated by plasma kallikrein from high molecular weight kininogen, has high affinity for B 2 receptors. Lys-2 receptor agonist, but with enhanced affinity at the human and rabbit B 1 receptor. The latter receptor type is optimally stimulated by kinin fragments devoid of the C-terminal arginine and secondarily produced by arginine carboxypeptidases(s), des-Arg 9 -BK and Lys-des-Arg 9 -BK [1] .
A new pathway of interest has been recently elucidated for kinin generation: the action of the neutrophil PR3 protease on high molecular weight kininogen releases a 13-mer, Met-Lys-BKSer-Ser also termed PR3-kinin [2] . Preliminary pharmacologic evaluation showed the absence of an affinity for recombinant B 2 receptors, a fair affinity for human B 1 receptors in a radioligand competition assay but a discrepant low potency to activate them (phospholipase C assay), and hypotensive effects in vivo mediated by both receptor subtypes, given that B 1 receptors were expressed in the animals [2] . The activation of the B 2 receptor at least must be accounted for by the generation of BK, Lys-BK and/or Met-Lys-BK, which are all known B 2 receptor agonists of nanomolar potencies at recombinant human or murine B 2 receptors [1] , and it was found indeed that blood plasma generates BK, Met-Lys-BK and BK fragments from Met-Lys-BK-Ser-Ser [2] .
The general hypothesis of the present study was that, if Met-Lys-BK-Ser-Ser has any physiological effects on vascular tissue, relevant activating peptidase(s) must be locally present to cleave the peptide into a high affinity receptor agonist. Thus, we have characterized the vascular actions of Met-Lys-BK-Ser-Ser with respect to BK receptor subtype affinity and possible metabolic activation by known peptidases. Affinities for 3 potential recombinant molecular targets, the BK B 1 and B 2 receptors and angiotensin converting enzyme (ACE), were estimated using separate radioligand displacement assays and an enzymatic assay. Well characterized vascular smooth muscle contractility assays, the rabbit aorta for the B 1 receptors [3] , the human umbilical vein and rabbit jugular vein for the B 2 receptor [4, 5] , have been exploited. These and other isolated tissues are suitable to identify activating and inactivating pathways in the sense that local metabolism distorts the concentration-effect relationship of agonist peptides. Indeed, the concentration of these peptides at the vicinity of receptors in the smooth muscle is not necessarily in equilibrium with that present in the bathing fluid of the tissue, the rate of metabolic change caused by peptidases within the tissue being occasionally faster than the rate of agonist diffusion from the bathing fluid to the extracellular space of the tissue (this paradigm is illustrated with several examples relevant for peptide receptor ligands elsewhere [6] ). We provide evidence for the paradoxical activation of Met-Lys-BK-Ser-Ser by ACE in vascular tissue. [12] . The fixed concentration of radioligand used in each binding assay is superior to its K D value determined for each molecular target, in such a manner that the vast majority of binding sites are available for the competition by unlabeled peptides.
Materials and methods

Radioligand binding competition assays
Enzymatic assay applied to recombinant ACE mutants
If Met-Lys-BK-Ser-Ser was an ACE substrate, it would be predicted that it would compete for the hydrolysis of another ACE substrate. We applied a described enzymatic assay based on the internally quenched fluorogenic substrate Abz-Phe-Arg-Lys(Dnp)-Pro-OH, obtained from Bachem (Torrance, CA, USA), knowing that it has an approximately equal low micromolar affinity for the two separate catalytic sites of ACE [12] . The sources of enzyme were membrane preparations from HEK 293a cells transiently expressing one of the recombinant ACE mutants inactivated for either catalytic site (N1-active; C1-active; with Lys substituting for two His residues in each catalytic site [13] ; also gifts of Prof. P. Corvol). The mutant ACE vectors were sequenced to confirm their identity. Membranes from transfected or untransfected (control) cells were prepared as described, with some variations [7] . Briefly, cells were homogenized (2 75-cm 2 flasks) in 0.25 ml sucrose buffer (250 mM sucrose, 20 mM tricine buffer, 1 mM PMSF, 10 mg/ml leupeptin, 2 mg/ml pepstatin, and 10 mg/ml soybean trypsin inhibitor, pH 7.5). In the sequential centrifugation steps applied, the first (600 g, 5 minutes) and second pellets (15 000 g, 5 minutes) were discarded; the third (150 000 g, 3 hours) pellets was resuspended in the same buffer as a source of membrane enzyme (normalized on the basis of protein concentration, BCA Protein Assay, Pierce). The enzymatic assay was performed as described [12] . Briefly, to 1 ml cuvettes containing Abz-Phe-Arg-Lys(Dnp)-Pro-OH (10 µM, dissolved in 0.1 M Tris HCl buffer containing 0.05 M NaCl and 10 µM ZnCl 2 , pH 7.0), were added 5 µg of membrane proteins and, optionally, a competitor (either BK or Met-Lys-BK-Ser-Ser in variable concentrations, or the ACE inhibitor enalaprilat). The heated (37°C) cuvette, submitted to magnetic agitation, was excited at 320 nm and the emitted fluorescence read continuously at 420 nm for 600 sec using an Aminco Bowman Series 2 luminescence spectrometer. The positive and linear slope of the time trace is proportional to the reaction velocity [12] and it has been calculated for the time interval 200-600 sec for each reaction.
Vascular smooth muscle contractility assays
A local ethics committee approved the animal experimentation. Rabbit aortic rings with intact endothelium (New Zealand White, 1.5 2 kg; Charles River Canada, Montreal, QC, Canada) were suspended under a tension of 2 g in 5-ml tissue baths containing oxygenated (95% O 2 /5% CO 2 ) and warmed [14] . Contractility studies were performed after 3 or 5.5 h of in vitro incubation because the response mediated by B 1 receptors is acquired in a time-and protein synthesis-dependent manner in this preparation [1] . The external jugular vein, an established bioassay for the rabbit bradykinin B 2 receptor [7] , has also been isolated from the animals and mounted in organ baths as described [15] . The institutional research ethics board approved the anonymous use of human umbilical cord segments obtained after elective cesarean section deliveries. Human umbilical cords stored at 4°C were obtained within 2 hr from cesareans. Segments of umbilical veins were dissected carefully from the cords and a metal rod was inserted into the lumen. Excess connective tissue was excised and rings (2-3 mm wide) were cut. Rings of umbilical veins were suspended under 2 g of baseline tension in 5-ml organ chambers containing oxygenated (95% O 2 -5% CO 2 solution, as described above. Umbilical vein rings, a contractile bioassay for B 2 receptor ligands [4] , were randomly assigned to agonist peptides and equilibrated for 3 h before the construction of cumulative-concentration curves. The full cumulative concentration-effect curves was recorded for each peptide; when the effect of Met-Lys-BK-Ser-Ser was suspected to be submaximal at the highest tested concentration, a large concentration of the reference agonist was added to record the maximal contractile effect mediated by the concerned receptor subtype. Ancillary experiments were conducted in the rabbit isolated aorta to control the effect of peptidase inhibitors on the concentration-effect relationship for angiotensin I or Lys-BK (recorded 2 or 4 h post-mounting), as explained in Results.
Drugs
Met-Lys-BK-Ser-Ser was synthesized via standard solid-phase methodology on Merrifield resin using Fmoc-chemistry, purified and analyzed (general methods as in [16] ). Both BK and Lysdes-Arg 9 -BK were purchased from Bachem. LF 16-0687
propyl]-2(S)-pyrrolidinecarboxamide, mesylate salt), a previously described nonpeptide B 2 receptor antagonist [17] , was a gift from Laboratoires Fournier (Daix, (mercaptomethyl-3-guanidinoethylthiopropanoic acid) from Calbiochem (La Jolla, CA). The latter compound is a high affinity inhibitor of arginine carboxypeptidases [19] . Other drugs were from Sigma-Aldrich (St. Louis, MO). (Fig. 1A, B) . The competing effect of the unlabeled form of each radioligand was established in these binding assays and was of nanomolar potency ( Ser is occasionally far from some experimental points. A possible explanation for these findings is a selectivity of Met-Lys-BK-Ser-Ser for one of the two catalytic sites found in tandem in ACE, for which both BK and enalaprilat have a strong affinity as a substrate (K M 240-540 nM) and blocker (nanomolar potency), respectively [13, 20] .
Data analysis
Results
Binding assays
Enzymatic assay applied to ACE mutants
The possible selectivity of Met-Lys-BK-Ser-Ser for one of the ACE catalytic sites was tested by competition for the fluorogenic substrate Abz-Phe-Arg-Lys(Dnp)-Pro-OH used at a concentration (10 µM) superior for the reported K m of either site (2.7 and 3.4 µM for the C-and N-domains, respectively) [12] . Membranes from untransfected HEK 293a cells did not catalyze the reaction (Fig. 2) . Either the N1-or the C1-active mutant of ACE hydrolyzed the substrate (positive slope of the fluorescence intensity as a function of time) and this reaction was virtually abolished by the addition of enalaprilat (100 nM) for either form of the recombinant enzyme. BK competed for the recombinant enzymes in a concentration-dependent manner, exhibiting nearly complete inhibition at a concentration equal to that of the substrate (10 µM). Met-Lys-BK-Ser-Ser had a lesser affinity for both forms of enzymes, the affinity gap between this peptide and BK being larger for the N1-active mutant than for the C1-active form (Fig. 2) .
Contractility assays
The human isolated umbilical vein, a bioassay for the B 2 receptors, is contracted by Met-Lys-BKSer-Ser (Fig. 3A) , this agonist being ~30-fold less potent than BK ( Fig. 3; table 2 ).
The rabbit isolated jugular vein has been extensively used as a contractile bioassay for the BK B 2
receptors [21] . The influence of endogenously expressed ACE is stronger in this tissue, as BK is known to be potentiated by captopril treatment of the tissues [5] , which has been reproduced using enalaprilat ( (Fig. 5A) . Thus, the difference of potency between the 2 stimulants is as large as in the radioligand displacement assay (Fig. 1A) . Tissue treatment with the powerful and specific nonpeptide B 1 receptor antagonist, compound 11 (1 nM) [18] , shifted the concentration-effect of Lys-des-Arg 9 -BK to the right and abolished the effect of the submaximal concentration of Met-Lys-BK-Ser-Ser, supporting that both agents contracted the tissue via B 1 receptors. The contractile effects of Met-Lys-BK-Ser-Ser or of Lys-des-Arg 9 -BK were not modified by co-incubation with the ACE inhibitor enalaprilat (100 nM inhibitor (1 µM), a blocker of arginine carboxypeptidases that removes the C-terminal arginine from native kinins ( Fig. 5A, B ; table 2). However, both of these peptidase activities exist in the isolated rabbit aorta as shown by previously published findings reproduced here in part with tissues from the animals exploited in Fig. 5A-B . A loss of function is determined by enalaprilat treatment (100 nM) for angiotensin I ( Fig. 5C ; table 2) M) for Lys-BK ( Fig. 5D ; table 2), especially for lower concentrations of these contractile agonists, because the effect of these agonists on AT 1 and B 1 receptors of the rabbit aorta is largely attributed to their in situ conversion into angiotensin II and Lys-des-Arg 9 -BK, respectively [22, 23] . The contractile potency of angiotensin II is not affected by enalaprilat (1 µM) [23] and that of Lys-des-Arg 9 - Fig. 5B ) or other arginine analogs that share the same peptidase target [22] .
Discussion
We found that the kinin generated by the neutrophil protease PR3, Met-Lys-BK-Ser-Ser, has only a micromolar affinity for BK B 2 receptors ( Fig. 1B; table 1 ), as previously reported [2] . The affinity of the PR3 kinin is marginally better at B 1 receptors (Fig. 1A) , but not as strong as previously reported by Kahn et al. [2] . Further, these authors reported that Met-Lys-BK-Ser-Ser activated phospholipase C in cells only at 1 µM, at variance with their own binding results, but possibly consistent with our affinity findings. Therefore, any significant vasoactive effect of this peptide must derive from its cleavage, leading to more conventional receptor agonists. Our basic hypothesis was that the peptidases present in freshly isolated blood vessels would process MetLys-BK-Ser-Ser into fragments that are active on kinin receptors.
The most salient findings are that Met-Lys-BK-Ser-Ser is a contractile agonist of the human umbilical or rabbit jugular veins variably less potent than BK but more potent than anticipated from the radioligand binding competition assay, and that the specific ACE inhibitor enalaprilat, further abates the effect of Met-Lys-BK-Ser-Ser (Figs. 3, 4) , suggesting that the peptidase activates this peptide by removing the C-terminal dipeptide. The resulting peptide, possibly MetLys-BK, is antagonized by a low concentration of the specific B 2 receptor antagonist LF in the umbilical vein. We recently identified ACE in endothelial cells of the human umbilical vein (tissue sections, immunohistochemistry) [11] ; in cultured endothelial cells derived from this vessel, the regulated expression of ACE has been described [11, 24, 25] . As previously reported [15] , enalaprilat did not influence the apparent potency of BK in the contractility assay. The alternate ACE inhibitor captopril also failed to potentiate BK in this preparation [4, 26] , suggesting that ACE is not abundant enough in the tissue to impair the equilibrium between BK concentrations in the bathing fluid and those at the vicinity of B 2 receptors that mediate the contraction of venous muscle cells. However, ACE presence is functionally revealed by the metabolic activation of Met-Lys-BK-Ser-Ser, and even more so in the rabbit jugular vein, a thinner tissue already known to be more influenced by endogenous ACE on the basis that ACE inhibition potentiates BK [5] . Thus, Met-Lys-BK-Ser-Ser reaches a nanomolar potency in this bioassay, being almost equipotent to BK in untreated jugular veins. However, enalaprilat cotreatment re-established the wide potency gap between the 2 peptides in favour of BK. previously reported [10, 11] . Both enalaprilat and BK have rather similar affinities for either catalytic site of somatic ACE [13, 20] , leading to apparently seamless radioligand saturation or competition curves. However, the irregular competition curve of [ 3 H]enalaprilat binding to recombinant ACE generated by Met-Lys-BK-Ser-Ser (Fig. 1C) suggested to us the possibility of a preferential occupancy of one catalytic site by this peptide. ACE mutants essentially confirmed this hypothesis, the gap of potency between BK and Met-Lys-BK-Ser-Ser as an ACE competitor being larger for the N-terminal active site than for the C-terminal one (Fig. 2) . The absolute micromolar kinin levels needed to inhibit ACE in either the binding or enzymatic assay should not be directly compared to affinity for receptors, because ACE is much more abundant than receptors in relevant cells and it mediates an irreversible hydrolysis reaction at a velocity that does not need to be maximal. We used an empirical pharmacological approach to identify peptidase(s) relevant for the activation of the 13-mer peptide in vascular tissue, but recent work identified peptides ending by Ser-Ser, Ser-Tyr and Ser-Pro as possessing an affinity for ACE in a fish protein hydrolysate [27] . These peptides acted as hydrolysis inhibitors of an ACE substrate, but it was not determined whether they were themselves ACE substrates.
Kahn et al. [2] stressed the activation of kinin B 1 receptors as a salient effect of Met-Lys-BK-SerSer. This 13-mer has a mediocre micromolar potency as a contractile agonist of the rabbit isolated aorta (Fig. 5) , the preparation on which the pharmacologic profile of the B 1 receptors was initially defined [21] . See Results for full description. A.
B.
C. b calculated using the one-site model; however, the competition curve has an irregular shape. maximal effect (%)
